Case Study: Large Pharmaceutical Company achieves gross-to-net predictability and Day-1 launch readiness with IntegriChain

Making Gross-to-Net a Reality for Expanding Oncology Therapy Manufacturer

Large Pharmaceutical Company, an expanding oncology therapy manufacturer preparing for U.S. launch, faced urgent gross-to-net (GTN) challenges — compliance and audit-readiness, tight month-end close timelines from its European parent, and limited time/resources to build a finance organization. About six months before BLA submission they engaged IntegriChain for GTN Advisory Services and ultimately selected IntegriChain’s GTN managed services and platform (GTN forecasts, GTN accruals, channel data aggregation, and rebate managed service).

IntegriChain delivered a GTN Roadmap, configured audit-ready GTN forecasts and accruals, aggregated channel data, and provided contracting/pricing advisory, then implemented the managed service ahead of launch. The solution was live for Day 1, enabled the month-end close accrual process to begin 30 days early, improved forecast accuracy and audit-readiness, and delivered rapid time-to-value — helping the Large Pharmaceutical Company meet launch timelines and operationalize GTN with transparent, compliant reporting.